Akèy › Ateroskleroz › Tennessee
Etid klinik pou Ateroskleroz nan Tennessee
9 etid pou Ateroskleroz ap chèche patisipan nan sit nan Tennessee.
Vil nan Tennessee
Tèks ofisyèl etid la (Anglè)
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
- Vanderbilt University School of Medicine (VUSM) - Vanderbilt Translational and Clinical Cardiovascular Research Center (VTRACC), Nashville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07448038Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
- WR-Clinsearch, LLC, Chattanooga
- Erlanger Health System, Chattanooga
- The Jackson Clinic, Jackson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07157774Clinical Assessment and Targeted Imaging to Characterize High-Risk Atherosclerotic Cardiovascular Disease of Survivors in SJLIFE
- St. Jude Children's Research Hospital, Memphis
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07594392Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Stern Cardiovascular Foundation Inc, Germantown
- Accellacare of Knoxville, Knoxville
- Cardiovascular Research of Knoxville North Knoxville Medical Center, Powell
- ak 1 plis
Ap rekriteFaz 3
Laj 45 a 99 · Tout sèks · Mizajou Sep 22, 2026 · NCT07037433Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- Southeast Renal Research Institute, Chattanooga
- Dialysis Clinic Inc - University Nephology, Knoxville
- Knoxville Kidney Center PLLC, Knoxville
- ak 2 plis
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05485961A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
- Research Site, Chattanooga
- Research Site, Chattanooga
- Research Site, Greeneville
- ak 9 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT07000357Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
- Novartis Investigative Site, Tullahoma
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Aug 7, 2026 · NCT06813911Pelacarsen Roll-over Extension Program
- Apex Cardiology Research Associates of Jackson, Jackson
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Jul 29, 2026 · NCT06875973Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
- Memphis VA Medical Center, Memphis, TN, Memphis
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Dec 17, 2025 · NCT02915198Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.